Trial
NCT02483871
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Duke University
Collaborators
—
Condition
Breast Cancer
Intervention
Rosuvastatin
Why stopped
Enrollment did not meet anticipated goals. Eligibility was a challenge.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-06-05